 |
| Attached files |
| File | Filename |
|---|
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R7.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R8.htm |
| EXCEL - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - PHARMA INVESTING NEWS, INC. | R9.htm |
| EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - PHARMA INVESTING NEWS, INC. | f10k022912_ex32z1.htm |
| EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - PHARMA INVESTING NEWS, INC. | f10k022912_ex31z2.htm |
| EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - PHARMA INVESTING NEWS, INC. | f10k022912_ex31z1.htm |
| 10-K - FORM 10-K ANNUAL REPORT - PHARMA INVESTING NEWS, INC. | f10k022912_10k.htm |
v2.4.0.6
|
Income Taxes
|
12 Months Ended |
|
Feb. 29, 2012
|
| Income Taxes |
|
| Income Taxes |
5. Income Taxes The Company has $90,697 of net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2031. The income tax benefit differs from the amount computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at February 29, 2012, the Company had no uncertain tax positions. | | | | | | | February 29, 2012 $ | February 28, 2011 $ | | | | | | | Net loss before taxes | | (84,697) | (6,000) | | Statutory rate | | 34% | 34% | | | | | | | Computed expected tax recovery | | 28,797 | 2,040 | | Valuation allowance | | (28,797) | (2,040) | | | | | | | Income tax provision | | – | – | The significant components of deferred income tax assets and liabilities at February 29, 2012 and February 28, 2011 are as follows: | | | | | | | | February 29, 2012 $ | | February 28, 2011 $ | | | | | | | | Net operating loss carried forward | | 30,837 | | 2,040 | | | | | | | | Valuation allowance | | (30,837) | | (2,040) | | | | | | | | Net deferred income tax asset | | – | | – | |
| X |
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690
+ Details
| Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by PHARMA INVESTING NEWS, INC. and has no official or unofficial affiliation with PHARMA INVESTING NEWS, INC.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
